DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,577,428,456 | -27.1% | 6,358,035 | -29.5% | 0.17% | -23.3% |
| Q2 2023 | $2,163,764,083 | -10.0% | 9,015,684 | -5.5% | 0.23% | -8.1% |
| Q1 2023 | $2,404,301,636 | -6.7% | 9,539,365 | -1.7% | 0.25% | -16.0% |
| Q4 2022 | $2,577,020,382 | -1.6% | 9,709,217 | -4.3% | 0.29% | -6.1% |
| Q3 2022 | $2,619,760,000 | -6.9% | 10,142,706 | -8.7% | 0.31% | -2.2% |
| Q2 2022 | $2,815,214,000 | -25.9% | 11,104,505 | -14.3% | 0.32% | -13.3% |
| Q1 2022 | $3,800,224,000 | -11.7% | 12,955,453 | -0.9% | 0.37% | -11.7% |
| Q4 2021 | $4,302,713,000 | +8.7% | 13,077,759 | +0.6% | 0.42% | +2.2% |
| Q3 2021 | $3,957,284,000 | +32.2% | 12,998,575 | +16.5% | 0.41% | +31.5% |
| Q2 2021 | $2,994,371,000 | +23.1% | 11,158,037 | +3.3% | 0.31% | +13.9% |
| Q1 2021 | $2,431,724,000 | -7.4% | 10,803,820 | -8.6% | 0.27% | -19.2% |
| Q4 2020 | $2,626,646,000 | +3.6% | 11,824,280 | +0.4% | 0.34% | -2.0% |
| Q3 2020 | $2,536,184,000 | +21.6% | 11,778,124 | -0.2% | 0.34% | +8.8% |
| Q2 2020 | $2,085,947,000 | +31.7% | 11,796,355 | +3.1% | 0.32% | +11.2% |
| Q1 2020 | $1,584,110,000 | -8.4% | 11,445,056 | +1.6% | 0.28% | +14.9% |
| Q4 2019 | $1,728,525,000 | +7.7% | 11,262,210 | +1.3% | 0.25% | +3.8% |
| Q3 2019 | $1,605,585,000 | +0.4% | 11,116,700 | -0.6% | 0.24% | -1.2% |
| Q2 2019 | $1,598,562,000 | +8.6% | 11,185,016 | +0.3% | 0.24% | +5.7% |
| Q1 2019 | $1,472,622,000 | +36.5% | 11,154,542 | +6.6% | 0.23% | +21.2% |
| Q4 2018 | $1,078,642,000 | -2.3% | 10,460,074 | +2.9% | 0.19% | +9.9% |
| Q3 2018 | $1,104,334,000 | +14.8% | 10,163,207 | +4.2% | 0.17% | +8.2% |
| Q2 2018 | $962,191,000 | +2.6% | 9,750,616 | +1.8% | 0.16% | -0.6% |
| Q1 2018 | $937,365,000 | -8.6% | 9,573,752 | -13.4% | 0.16% | -7.0% |
| Q4 2017 | $1,025,838,000 | +1.0% | 11,051,908 | -6.6% | 0.17% | +6.8% |
| Q3 2017 | $1,015,477,000 | +10.7% | 11,838,161 | +8.9% | 0.16% | -11.5% |
| Q2 2017 | $916,971,000 | -10.8% | 10,865,866 | -9.6% | 0.18% | -11.2% |
| Q1 2017 | $1,028,475,000 | +17.1% | 12,024,740 | +6.5% | 0.20% | +7.9% |
| Q4 2016 | $878,491,000 | +7.2% | 11,285,853 | +8.0% | 0.19% | +5.6% |
| Q3 2016 | $819,359,000 | -28.5% | 10,452,328 | -7.9% | 0.18% | -32.1% |
| Q2 2016 | $1,146,506,000 | +3.9% | 11,351,547 | -2.4% | 0.26% | -1.5% |
| Q1 2016 | $1,103,496,000 | -11.0% | 11,632,892 | -12.8% | 0.27% | -8.5% |
| Q4 2015 | $1,239,521,000 | +11.4% | 13,345,416 | +2.2% | 0.29% | +6.5% |
| Q3 2015 | $1,112,410,000 | -32.9% | 13,054,926 | -32.6% | 0.28% | -48.9% |
| Q2 2015 | $1,658,439,000 | +120.4% | 19,376,540 | +118.6% | 0.54% | +113.4% |
| Q1 2015 | $752,407,000 | +47.4% | 8,862,267 | +48.8% | 0.25% | +38.3% |
| Q4 2014 | $510,342,000 | +23.1% | 5,954,271 | +9.1% | 0.18% | +36.6% |
| Q3 2014 | $414,524,000 | +30.8% | 5,455,700 | +35.5% | 0.13% | +32.7% |
| Q2 2014 | $317,032,000 | +34.3% | 4,026,846 | +27.9% | 0.10% | +16.1% |
| Q1 2014 | $236,145,000 | -32.9% | 3,148,591 | -30.9% | 0.09% | -31.5% |
| Q4 2013 | $351,708,000 | +71.2% | 4,555,841 | +53.8% | 0.13% | +54.9% |
| Q3 2013 | $205,380,000 | +8.8% | 2,962,788 | -0.7% | 0.08% | +3.8% |
| Q2 2013 | $188,800,000 | – | 2,982,630 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |